Takeda Pharmaceutical Company Limited (TOKYO:4502):   Delivered substantial profit growth versus prior year   Underlying Revenue grew +6.9%, with Takeda’s Growth Drivers (G… Read More

We initiate coverage on Takeda Pharmaceutical with a neutral rating and a DCF based target price of ¥ 5,200. We expect the Entyvio, Ninlaro and Trintellix trio to bring about much requir… Read More

It wasn't all that far along into this calendar year that I found myself sitting at this desk, on to which I had spilled a fairly large number of pills. I had grouped them in neat little row… Read More